Trastuzumab-Induced Cardiotoxicity

Lisa Stegall Moss

Mandy Fields Starbuck

Deborah K. Mayer

Elaine Brooks Harwood

Jana Glotzer

drug therapy, cardiotoxicity, Assessment
ONF 2009, 36(6), 676-685. DOI: 10.1188/09.ONF.676-685

Purpose/Objectives: To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education.

Data Sources: Literature regarding cardiotoxicity and trastuzumab in breast cancer.

Data Synthesis: Trastuzumab was approved in 2006 for use in the adjuvant setting. A small percentage of women (~ 4%) developed heart failure during or after treatment. However, the trials excluded women with cardiac disease. Current screening for cardiotoxicity relies on sequential left ventricular function measurements with either echocardiography or multigated acquisition scanning at baseline and every three months. Treatment modifications are recommended if changes from baseline are detected. Long-term and late effects have yet to be determined.

Conclusions: Although a small number of women experienced cardiotoxicity in the adjuvant setting, an increase may be seen because women with preexisting heart disease receive this treatment. Guidelines and tools will be helpful for appropriate and consistent screening of cardiac risk factors and disease prior to initiation of trastuzumab and for monitoring during and after administration.

Implications for Nursing: Nurses are instrumental in assessing, monitoring, and treating women receiving trastuzumab. Implementing guidelines to promote adherence to recommended monitoring is important in the early detection of cardiotoxicity in this population. Educating women about their treatment and side effects is an important aspect of care.

Jump to a section


    American Cancer Society. (2009a). Breast cancer facts and figures 2009a. Atlanta, GA: Author.
    American Cancer Society. (2009b). Cancer facts and figures 2009. Atlanta, GA: Author.
    Baselga, J., Perez, E.A., Pienkowski, T., & Bell, R. (2006). Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11(Suppl. 1), 4-12.
    Bird, B.R., & Swain, S. (2008). Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clinical Cancer Research, 14(1), 14-24.
    Cleveland Clinic Cancer Center. (2005). Chemotherapy drugs: Trastuzumab. Retrieved January 11, 2008, from
    Cook-Bruns, N. (2001). Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology, 61(Suppl. 2), 58-66.
    Criteria Committee of the New York Heart Association. (1994). Nomenclature and criteria for diagnosis of the heart and great vessels (9th ed.). Boston: Little, Brown, and Co.
    Demark-Wahnefried, W., Aziz, N.M., Rowland, J.H., & Pinto, B.M. (2005). Riding the crest of the teachable moment: Promoting longterm health after the diagnosis of cancer. Journal of Clinical Oncology, 23(24), 5814-5830.
    Ewer, M.S., Vooletich, M.T., Durand, J.B., Woods, M.L., Davis, J.R., Valero, V., et al. (2005). Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23(31), 7820-7826.
    Ewer, S.M., & Ewer, M.S. (2008). Cardiotoxicity profile of trastuzumab. Drug Safety, 31(6), 459-467.
    Fleisher, L.A., Beckman, J.A., Brown, K.A., Calkins, H., Chaikof, E., Fleischmann, L.E., et al. (2007). ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Retrieved February 7, 2008, from:
    Genentech, Inc. (2009a). Herceptin might be right for you. Retrieved October 10, 2009, from
    Genentech, Inc. (2009b). Herceptin (trastuzumab) [Prescribing information]. Retrieved October 10, 2009, from
    Gonzalez-Angulo, A.M., Hortobagyi, G.N., & Esteva, F.J. (2006). Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist, 11(8), 857-867.
    Grazette, L.P., Boecker, W., Matsui, T., Semigran, M., Force, T.L., Hajjar, R.J., et al. (2004). Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes. Journal of the American College of Cardiology, 44(11), 2231-2238.
    Guglin, M., Cutro, R., & Mishkin, J. (2008). Trastuzumab-induced cardiomyopathy. Journal of Cardiac Failure, 14(5), 437-444.
    Guntinas-Lichius, O., & Wittekindt, C. (2003). The role of growth factors for disease and therapy in diseases of the head and neck. DNA and Cell Biology, 22(9), 593-606.
    Horner, M.J., Ries, L.A.G., Krapcho, M., Neyman, N. Aminou, R., Howlader, N., et al. (2009). SEER cancer statistics review, 1975-2006. Bethesda, MD: National Cancer Institute.
    Hudis, C.A. (2007). Trastuzumab—Mechanism of action and use in clinical practice. New England Journal of Medicine, 357(1), 9-51.
    Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Retrieved October 13, 2009, from
    Menna, P., Salvatorelli, E., & Minotti, G. (2008). Cardiotoxicity of antitumor drugs. Chemical Research in Toxicology, 21(5), 978-989.
    Montemurro, F., Redana, S., Valabrega, G., Martinello, R., Aglietta, M., & Palmiero, R. (2008). Trastuzumab-related cardiotoxicity in the Herceptin Adjuvant Trial. Journal of Clinical Oncology, 26(12), 2052-2053.
    National Cancer Institute. (2008). Surveillance Epidemiology, and End Results: Breast cancer facts. Retrieved February 23, 2009, from
    National Heart Lung and Blood Institute. (2003). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Retrieved October 7, 2009, from
    National Institutes of Health. (2009). Drug information: Trastuzumab. Retrieved February 23, 2009, from
    Popat, S., & Smith, I.E. (2008). Therapy insight: Anthracyclines and trastuzumab—The optimal management of cardiotoxic side effects. Nature. Clinical Practice Oncology, 5(6), 324-335.
    Pugatsch, T., Abedat, S., Lotan, C., & Beeri, R. (2006). Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Research, 8(4), R35.
    Sengupta, P.P., Northfelt, D.W., Gentile, F., Zamorano, J.L., & Khandheria, B.K. (2008). Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clinic Proceedings, 83(2), 197-203.
    Smith, L. (2007). Diagnosis and management of chronic heart failure in adults. American Family Physician, 112, e154-e235. Retrieved October 13, 2009, from
    Telli, M.L., Hunt, S.A., Carlson, R.W., & Guardino, A.E. (2007). Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. Journal of Clinical Oncology, 25(23), 3525-3533.
    U.S. Food and Drug Administration. (2006). FDA expands use of trastuzumab for early-stage breast cancer after primary therapy. Retrieved July 17, 2007, from
    Viale, P.H., & Yamamoto, D.S. (2008). Cardiovascular toxicity associated with cancer treatment. Clinical Journal of Oncology Nursing, 12(4), 627-638.